Kim Woorim, Cho Young-Ah, Kim Dong-Chul, Jo A-Ra, Min Kyung-Hyun, Lee Kyung-Eun
College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.
College of Pharmacy, Gyeongsang National University, Jinju 52828, Korea.
Cancers (Basel). 2021 Oct 30;13(21):5465. doi: 10.3390/cancers13215465.
Targets of immune checkpoint inhibitors (ICIs) regulate immune homeostasis and prevent autoimmunity by downregulating immune responses and by inhibiting T cell activation. Although ICIs are widely used in immunotherapy because of their good clinical efficacy, they can also induce autoimmune-related adverse events. Thyroid-related adverse events are frequently associated with anti-programmed cell death 1 (PD-1) or anti-programmed cell death-ligand 1 (PD-L1) agents. The present study aims to investigate the factors associated with thyroid dysfunction in patients receiving PD-1 or PD-L1 inhibitors and to develop various machine learning approaches to predict complications. A total of 187 patients were enrolled in this study. Logistic regression analysis was conducted to investigate the association between such factors and adverse events. Various machine learning methods were used to predict thyroid-related complications. After adjusting for covariates, we found that smoking history and hypertension increase the risk of thyroid dysfunction by approximately 3.7 and 4.1 times, respectively (95% confidence intervals (CIs) 1.338-10.496 and 1.478-11.332, = 0.012 and 0.007). In contrast, patients taking opioids showed an approximately 4.0-fold lower risk of thyroid-related complications than those not taking them (95% CI 1.464-11.111, = 0.007). Among the machine learning models, random forest showed the best prediction, with an area under the receiver operating characteristic of 0.770 (95% CI 0.648-0.883) and an area under the precision-recall of 0.510 (95%CI 0.357-0.666). Hence, this study utilized various machine learning models for prediction and showed that factors such as smoking history, hypertension, and opioids are associated with thyroid-related adverse events in cancer patients receiving PD-1/PD-L1 inhibitors.
免疫检查点抑制剂(ICI)的靶点通过下调免疫反应和抑制T细胞活化来调节免疫稳态并预防自身免疫。尽管ICI因其良好的临床疗效而广泛应用于免疫治疗,但它们也会诱发与自身免疫相关的不良事件。甲状腺相关不良事件常与抗程序性细胞死亡蛋白1(PD-1)或抗程序性细胞死亡配体1(PD-L1)药物相关。本研究旨在调查接受PD-1或PD-L1抑制剂治疗的患者发生甲状腺功能障碍的相关因素,并开发各种机器学习方法来预测并发症。本研究共纳入187例患者。进行逻辑回归分析以研究这些因素与不良事件之间的关联。使用各种机器学习方法来预测甲状腺相关并发症。在调整协变量后,我们发现吸烟史和高血压使甲状腺功能障碍的风险分别增加约3.7倍和4.1倍(95%置信区间(CI)为1.338 - 10.496和1.478 - 11.332,P = 0.012和0.007)。相比之下,服用阿片类药物的患者发生甲状腺相关并发症的风险比未服用者低约4.0倍(95% CI为1.464 - 11.111,P = 0.007)。在机器学习模型中,随机森林表现出最佳预测效果,其受试者工作特征曲线下面积为0.770(95% CI为0.648 - 0.883),精确召回率曲线下面积为0.510(95% CI为0.357 - 0.666)。因此,本研究利用各种机器学习模型进行预测,并表明吸烟史、高血压和阿片类药物等因素与接受PD-1/PD-L1抑制剂治疗的癌症患者的甲状腺相关不良事件有关。